Cell-Penetrating Peptides: As a Promising Theranostics Strategy to Circumvent the Blood-Brain Barrier for CNS Diseases

Curr Drug Deliv. 2020;17(5):375-386. doi: 10.2174/1567201817666200415111755.

Abstract

The passage of therapeutic molecules across the Blood-Brain Barrier (BBB) is a profound challenge for the management of the Central Nervous System (CNS)-related diseases. The ineffectual nature of traditional treatments for CNS disorders led to the abundant endeavor of researchers for the design the effective approaches in order to bypass BBB during recent decades. Cell-Penetrating Peptides (CPPs) were found to be one of the promising strategies to manage CNS disorders. CPPs are short peptide sequences with translocation capacity across the biomembrane. With special regard to their two key advantages like superior permeability as well as low cytotoxicity, these peptide sequences represent an appropriate solution to promote therapeutic/theranostic delivery into the CNS. This scenario highlights CPPs with specific emphasis on their applicability as a novel theranostic delivery system into the brain.

Keywords: Cell-penetrating peptide; blood-brain barrier; central nervous system; drug delivery; theranostics; translocation..

Publication types

  • Review

MeSH terms

  • Animals
  • Blood-Brain Barrier / metabolism*
  • Cell-Penetrating Peptides / administration & dosage*
  • Central Nervous System Diseases / diagnosis*
  • Central Nervous System Diseases / drug therapy*
  • Drug Stability
  • Humans
  • Precision Medicine

Substances

  • Cell-Penetrating Peptides